By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
NASA set for first crewed moon return in over half a century - 2Truly amazing Palaces: Which Is Your Number one?
- 3Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- 4Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- 5Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- US EPA will reassess safety of herbicide paraquat, says its chief
- The best overlooked performances of 2025
- Instructions to Pick the Right Dental Expert for Teeth Substitution
- Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’
- 12 times rockets and spacecraft crashed and burned in 2025
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- Grasping the Qualifications Among Separation and Dissolution
- Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
